Anti-TNFα agents and interleukin-17A inhibitor Secukinmuab have similar effects in improvement of ASAS20, ASAS40, and safety: a meta-analysis
نویسندگان
چکیده
Objective: The aim of this study was to indirectly compare the efficacy and safety of anti-tumor necrosis factor α (TNFα) agents and an interleukin (IL)-17A inhibitor Secukinmuab for the treatment of ankylosing spondylitis (AS). Methods: Literatures were searched in Pubmed, Medline, Embase and the Cochrane library to screen citations from January 1996 to December 2015. The mixed treatment comparison (MTC) meta-analysis within a Bayesian framework was performed by WinBUGS14 software. The proportion of patients reaching ASAS20 and ASAS40 improvement by the assessment of Spondyloarthritis International Society response criteria index at week 12 was used as efficacy end point. Results: There was no significant difference between the five anti-TNFα agents and Secukinmuab regarding their efficacy and safety. We found that infliximab may have a better effect in improving ASAS20 than the other drugs and ct-p13 may have a better effect in improving ASAS40 than the other drugs during 12 week therapy, although there were no statistical differences. Conclusion: Allsix agents have similar effects in improvement of ASAS20, ASAS40, and safety. However, infliximab and ct-p13 trended to be superior to the other four agents in terms of ASAS20 and ASAS40 during 12 week treatment. IL-17A can be a potential therapeutic target in spondyloarthritis.
منابع مشابه
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
INTRODUCTION Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS A targeted literature review was conducted to identify randomized clinical trials for adalimumab, in...
متن کاملMolecular docking and druggability studies of terpenoid-derived metabolites from marine sponges as IL-17A inhibitors
In this study, physicochemical properties of 49 compounds extracted from anti-inflammatory sponge species with the aim of ADMET test and Lipinski rule of five have been determined. Fourteen compounds, which showed best results, were subjected to molecular docking studies with IL-17. Among these compounds, Four compounds with low binding energy were obtained. These compounds, namely, frondosins ...
متن کاملGolimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
OBJECTIVE Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). METHODS 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed ...
متن کاملEfficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with impact on axial skeleton, peripheral joints and enthuses, and it may result in severe disabilities of those parts. Tumor necrosis factor-α (TNF-α) inhibitors are considered as an effective treatment for patients with active AS. In this study, we conducted a network meta-analysis to compare the clinical outcomes of active AS p...
متن کاملAdalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
OBJECTIVE To evaluate the long-term safety and efficacy of adalimumab in patients with ankylosing spondylitis (AS) and total spinal ankylosis (TSA). DESIGN Patients (n = 315) with active AS were randomised in a 2:1 ratio to receive adalimumab 40 mg every other week or placebo for 24 weeks followed by open-label adalimumab for up to 5 years. Two-year efficacy and safety data for 11 patients wi...
متن کامل